CN116058506A - 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 - Google Patents
含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 Download PDFInfo
- Publication number
- CN116058506A CN116058506A CN202310177885.1A CN202310177885A CN116058506A CN 116058506 A CN116058506 A CN 116058506A CN 202310177885 A CN202310177885 A CN 202310177885A CN 116058506 A CN116058506 A CN 116058506A
- Authority
- CN
- China
- Prior art keywords
- rice bran
- fatigue
- beta
- fatty alkanol
- bran fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 40
- 235000009566 rice Nutrition 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 240000007594 Oryza sativa Species 0.000 title 1
- 241000209094 Oryza Species 0.000 claims abstract description 39
- 239000005715 Fructose Substances 0.000 claims abstract description 24
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- 235000020733 paullinia cupana extract Nutrition 0.000 claims abstract description 16
- 229930091371 Fructose Natural products 0.000 claims abstract description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 11
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 11
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 11
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229960003624 creatine Drugs 0.000 claims abstract description 11
- 239000006046 creatine Substances 0.000 claims abstract description 11
- 239000001177 diphosphate Substances 0.000 claims abstract description 11
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract description 11
- 235000011180 diphosphates Nutrition 0.000 claims abstract description 11
- 235000021119 whey protein Nutrition 0.000 claims abstract description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 8
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 8
- 229960002477 riboflavin Drugs 0.000 claims abstract description 8
- 229960003495 thiamine Drugs 0.000 claims abstract description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 8
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 8
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 8
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 49
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 44
- 238000002156 mixing Methods 0.000 claims description 36
- 229960002666 1-octacosanol Drugs 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003094 microcapsule Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000007599 discharging Methods 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 11
- 230000009182 swimming Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000002929 anti-fatigue Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000037149 energy metabolism Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000003444 Paullinia cupana Species 0.000 description 2
- 235000000556 Paullinia cupana Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007105 physical stamina Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
- B01J13/043—Drying and spraying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种含米糠脂肪烷醇的消除疲劳的组合物及其制备方法,属于保健食品技术领域。包括组分:乳清蛋白、胶原蛋白肽、结晶果糖、β‑烟酰胺单核苷酸、β‑羟基‑β‑甲基丁酸钙、1,6‑二磷酸果糖、瓜拉那提取物、米糠脂肪烷醇、肌酸、维生素B1、维生素B2、牛磺酸。本发明通过提供多种不同的有益成分,从不同角度去解决减轻生理性的疲劳和病理性疲劳带来的副作用。
Description
技术领域
本发明属于保健食品技术领域,涉及一种含米糠脂肪烷醇具有快速恢复体能、消除疲劳的组合物,具体地说涉及一种含米糠脂肪烷醇的消除疲劳的组合物及其制备方法。
背景技术
疲劳是一种及其常见的生理现象,指“机体生理过程不能续持其功能在特定水平和或不能维持预定的运动强度”的机体运动能力下降的一种状态,引起疲劳的原因常见有用眼过度、肥胖、缺乏运动、睡眠和心理问题和药物等。疲劳可分为生理性的疲劳和病理性疲劳。生理性疲劳一般引起的原因可能跟劳累、剧烈运动、睡眠不足、不科学的减肥有关,经过适当休息可以得到缓解的。而病理性的疲劳,则不易通过休息得到缓解,排除消耗性疾病以外,多属于“慢性疲劳综合征”,表现为无器质性病变,但处于长期原因不明的强度疲劳感觉或身体不适。长期处于此类疲劳状态会引起神经系统紊乱、心脑血管、消化系统不适、内分泌紊乱以及免疫力下降,导致失眠、高血压、消化不良等疾病,因此,对于这类处于病理性疲劳的人群给予一定的人为干预是非常有必要的。
抗疲劳就是通过一些方法手段来抵消这种疲劳的感觉,从而使人感觉轻松有精神。轻度和非病理性疲劳可以通过调整睡眠和饮食结构、加强运动和按摩等基础保健手段加以恢复,能够起到一定效果,而长期疲劳和病理性疲劳则需要在调节饮食起居的基础上使用一些保健和治疗手段。
近年来,在民间医学和现代科学实验基础上,不少学者在中药抗疲劳方面做了大量的工作,对其化学成分和作用机理进行了探讨。
常见的抗疲劳中药包人参、西洋参、红景天、淫羊藿等,有较好的增强能量代谢的作用,有利于提高运动能力。除此之外,麦冬、党参、黄芪、枸杞子等均对抗疲劳有一定的疗效,现有技术中抗疲劳产品多为药物和保健品,服用不便,口味欠佳,导致患者的依从性差,一种能够易于获得、购入成本更小、口味和疗效俱佳的抗疲劳产品是市场急需的。
米糠脂肪烷醇,是以米糠为原料制得米糠蜡,之后经皂化、提取、过滤等工艺制成的一种高级脂肪醇混合物。其主要成分为二十八烷醇,是一种安全有效的功能性因子。根据小白鼠口服试验,二十八烷醇的LD50为18000mg/kg以上,安全性比食盐(LD50=3000mg/kg)还高,同时经小鼠精子畸变试验、小鼠骨髓微核试验和Ames试验等均呈现阴性。作为一种天然醇,二十八烷醇具有良好的生物降解性,易为动物体吸收及利用。二十八烷醇是天然存在的高级脂肪醇。人们最初发现在大米胚芽和小麦胚芽中含有微量的二十八烷醇,随着研究方法的改进和不断深入,发现二十八烷醇以结合态(蜡酯形式)或游离态广泛分布于动物的表皮与内脏、昆虫分泌的蜡质以及植物的根、茎、叶、壳、籽仁的脂质中。在国外的一些含有二十八烷醇功能性饮料、饼干、保健品等相对来说品种是比较丰富的,但我国在此领域还是存在空白的,一是政策法规的方面的问题,另外就是消费者的需求和教育不够。
发明内容
本发明的目的在于提供一种含米糠脂肪烷醇具有快速恢复体能、消除疲劳的组合物。
为了实现上述目的,本发明采用以下技术方案:
一种含米糠脂肪烷醇的消除疲劳的组合物以质量份计算,含有以下组分:
乳清蛋白25-50
胶原蛋白肽10-20
结晶果糖10-20
β-烟酰胺单核苷酸5-15
β-羟基-β-甲基丁酸钙1-10
1,6-二磷酸果糖1-10
瓜拉那提取物1-5
米糠脂肪烷醇微胶囊0.5-3
肌酸0.5-3
维生素B1 0.5-3
维生素B2 0.5-3
牛磺酸0.1-1。
特别地,所述米糠脂肪烷醇微胶囊由以下步骤制备:
(1)称取二十八烷醇提取物,加热熔化后,加入Tween80,搅拌均匀,作为油相;
(2)将壁材溶解于水中,作为水相;
(3)在加热装置中,边搅拌边将油相逐渐加入到水相中,搅拌乳化喷雾干燥。
特别地,所述壁材包括以质量份计算,含有以下组分:
阿拉伯胶 1
麦芽糊精 1
β-环糊精 2。
特别地,所述步骤(1)中,二十八烷醇提取物与Tween80的比例1g:8ml。
特别地,所述步骤(2)中,二十八烷醇提取物与壁材的质量比为1:9,壁材与水的比例为9g:80ml。
特别地,所述步骤(3)中,搅拌乳化的时间为≥4h,加热温度≥80℃,搅拌速率≥6000rpm。
一种含米糠脂肪烷醇的消除疲劳的组合物的制备方法,包括以下步骤:
(1)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合,得物料A;
物料A、米糠脂肪烷醇进行混合,得物料B;
物料B和瓜拉那提取物进行混合,得物料B;
物料C和1,6-二磷酸果糖进行混合,得预混料;
(2)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀,出料。
米糠脂肪烷醇一种生物安全性极高的功能性天然产物。由于天然提取的二十八烷醇绿色、安全,人体每日只需摄入少量的米糠脂肪烷醇即能起到调节生理功能的作用。适合各类人群,当二十八烷醇在体内调节脂类代谢时,一定会对体内的能量代谢产生连锁反应。因此,深入研究二十八烷醇在体内能量代谢过程中的调节作用,对于合理、有效使用二十八烷醇,发挥其生理功能具有重要的意义。
与现有技术相比,本发明的有益效果为:
1.通过加入米糠脂肪烷醇,米糠脂肪烷醇在动物和植物中均有少量分布,目前主要从小麦、米糠等中提取。米糠脂肪烷醇是国际上被公认为一种具有缓解体力疲劳的一元高级醇物质。二十八烷醇具有积极促进人体生理功功能的功效,其主要功效表现为:1)提高肌体运动耐受力,缓解疲劳;2)增强新城代谢;3)降血脂,抗动脉粥样硬化;4)抑制肝脏氧代谢紊乱与急性肝损伤。
2.运动性疲劳被定义为:运动时细胞内能量物质的消耗、肌肉能力下降、肌肉兴奋性和活动性改变等综合起来,当这些因素变化达到一定的临界值时时,为保护机体免于衰竭,以运动性疲劳的形式表现出来。本发明正是基于这一理论,通过加入β-烟酰胺单核苷酸,β-烟酰胺单核苷酸天然存在于活细胞中,是辅酶1NAD+(烟酰胺腺嘌呤二核苷酸)的前体。可适当延长寿命。真正发挥抗衰老作用的是一种称为烟酰胺腺嘌呤二核苷酸(NAD+)的重要能量代谢物。
随着年龄增长,NAD+水平的降低导致DNA修复能力下降,DNA损伤积累,驱动衰老进程。NAD+在细胞中参与细胞呼吸作用,促进能量代谢过程(如葡萄糖、脂肪、氨基酸的氧化)。NAD+不仅是活细胞中几百种氧化还原反应的辅酶,它还作为底物参与调节细胞存活、细胞凋亡、DNA修复、免疫应答、昼夜节律等多种生理功能。
米糠脂肪烷醇在饮料中的应用最多,如将米糠脂肪烷醇乳化液与含有果葡糖浆等配料的蔗糖溶液复配,通过高温均质、加热杀菌等步骤获得功能性运动饮料,通过科学家研究表明适量服用含有二十八烷醇饮料的运动员血脂代谢水平明显改善,运动能理得到显著提高,而且能延缓运动疲劳。
3.长时间运动,血糖浓度快速下降,肌糖原的消耗导致人体的运动能力减弱,而血糖浓度下降将直接影响中枢神经系统的机能,产生疲劳或头晕现象。本发明通过加入结晶果糖、1,6-二磷酸果糖,影响糖代谢。结晶果糖有水果香味,热值低,在体内代谢比葡萄糖快,易被机体吸收利用,且不依赖胰岛素,血糖负担小。果糖在人体内能促进有益细菌如双歧杆菌的生长繁殖,抑制有害菌生长,改善肠胃功能和代谢,降低血脂,不致龋齿,是糖尿病人、肥胖病人、儿童的理想甜味剂。
二磷酸果糖是葡萄糖代谢过程中的重要的中间产物,磷酸肌酸是产生ATP的重要底物,因为ATP的氧化磷酸化.,必须需要磷酸肌酸的参与。一种新型能量代谢赋活剂,能够增加心肌细胞内磷酸肌酸以及ATP的含量,从而可以减少心肌损伤。
4.蛋白质是组成人体一切细胞、组织的重要成分。机体所有重要的组成部分都需要有蛋白质的参与。一般说,蛋白质约占人体全部质量的18%,最重要的还是其与生命现象有关。蛋白质(protein)是生命的物质基础,是有机大分子,是构成细胞的基本有机物,是生命活动的主要承担者。
当胶原蛋白不足时,不仅皮肤及骨骼会出现问题,对内脏器官也会产生不利影响。也就是说,胶原蛋白是维持身体正常活动所不可缺少的重要成分。同时也是使身体保持年轻、防止老化的物质。另外,胶原蛋白还可以预防疾病,改善体质,对美容和健康都很有帮助。
胶原蛋白肽是一类以富含胶原蛋白的新鲜动物组织(包括皮、骨、筋、腱、鳞等)为原料,经过提取、水解、精制生产的,相对分子质量低于10000Da的产品。胶原蛋白富含人体需要的甘氨酸、脯氨酸、羟脯氨酸等氨基酸。胶原蛋白是细胞外基质中最重要的组成部分。胶原蛋白肽,可以被人体主动且无障碍吸收,无需消化,供身体组织充分利用。因此本品添加乳清蛋白与胶原蛋白。
5.本发明添加瓜拉那提取物,减少疲劳,增强活力。瓜拉那提取物是从瓜拉那种子种提取的物质,所含的caffee,能够逐渐而缓慢地刺激神经,刺激维持的有效期长,而且刺激比较温和,对人体没有危害,而其他来源的产品通常起效快,但持续时间短。
6.本品添加β-羟基-β-甲基丁酸钙、牛磺酸和维生素B1、维生素B2、肌酸,影响能量代谢。HMB-Ca可用于促进肌肉生长,增强免疫力,降低体内胆固醇和低密度脂蛋白(LDL)水平以减少冠心病和心血管疾病的发生,还能增强人体固氮能力,维持体内蛋白质水平,应用广泛。牛磺酸可与胰岛素受体结合,促进细胞摄取和利用葡萄糖,加速糖酵解,降低血糖浓度。
具体实施方式
为了更好地理解本发明,下面结合具体实施例对本发明作进一步的描述,其中实施例中使用的术语是为了描述特定的具体实施方案,不构成对本发明保护范围的限制。
本发明中:
瓜拉那提取物又名瓜拿那提取物、瓜拉纳提取物等,英文名为Guarana extract;CAS No.:84929-28-2。
下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
米糠脂肪烷醇微胶囊制备:
称取0.5质量份二十八烷醇提取物,90℃加热熔化后,加入4体积份Tween80,搅拌均匀,作为油相。将4.5质量份复合壁材(由阿拉伯胶、麦芽糊精、β-环糊精按照1:1:2的比例组成)溶解于40体积份的水中,作为水相。在加热装置中(80℃),边搅拌边将油相逐渐加入到水相中,以6000prm的速度搅拌乳化4h,形成原乳,再进行喷雾干燥,即得,测量其微胶囊包封率,为85±5%。
实施例1
一种含米糠脂肪烷醇的消除疲劳的组合物的制备,
(1)称量:每100g组合物由以下含量的原料称量:
乳清蛋白 35g
胶原蛋白肽 20g
结晶果糖17.8g
β-烟酰胺单核苷酸6g
β-羟基-β-甲基丁酸钙6g
1,6-二磷酸果糖6g
瓜拉那提取物4g
米糠脂肪烷醇微胶囊3g
肌酸1g
维生素B1 0.5g
维生素B2 0.5g
牛磺酸0.2g
(2)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合5min为物料A;物料A、米糠脂肪烷醇微胶囊进行混合5min为物料B;物料B和瓜拉那提取物进行混合5min为物料C;物料C和1,6-二磷酸果糖进行混合5min,为预混料;
(3)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀30min,出料密封备用。
实施例2
(1)称量:每100g组合物由以下含量的原料称量:
(2)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合5min为物料A;物料A、米糠脂肪烷醇微胶囊进行混合5min为物料B;物料B和瓜拉那提取物进行混合5min为物料C;物料C和1,6-二磷酸果糖进行混合5min,为预混料;
(3)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀30min,出料密封备用。
实施例3
(1)称量:每100g组合物由以下含量的原料称量:
(2)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合5min为物料A;物料A、米糠脂肪烷醇微胶囊进行混合5min为物料B;物料B和瓜拉那提取物进行混合5min为物料C;物料C和1,6-二磷酸果糖进行混合5min,为预混料;
(3)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀30min,出料密封备用。
实施例4
(1)称量:每100g组合物由以下含量的原料称量:
(2)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合5min为物料A;物料A、米糠脂肪烷醇微胶囊进行混合5min为物料B;物料B和瓜拉那提取物进行混合5min为物料C;物料C和1,6-二磷酸果糖进行混合5min,为预混料;
(3)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀30min,出料密封备用。
小鼠动物实验
根据《保健食品理化及卫生指标检验与评价技术指导原则(2020年版)》以及《保健食品季检验与评价技术规范(2003年版)》的相关检测项目进行测试;两者具有相同的测试项目时,以《保健食品理化及卫生指标检验与评价技术指导原则(2020年版)》的记载为准。
1.材料和方法
材料
仪器与耗材:
游泳箱、钠石灰、白凡士林、电子天平、小鼠灌胃器。
动物:SPF级雄性KM小鼠,体质量20±2g,60只。
2方法
饲养条件及分组
小鼠5只一笼,自由饮食饮水,饲养于光线及温湿度控制房间内:温度21±2℃,湿度50±10%,12h/12h明暗周期(20:00开灯,8:00关灯),所有动物实验操作比照NIH颁布实验动物福利及使用指导原则进行。
小鼠运抵后适应一周进入实验。每组10只,按照随机区组设计方法分为6组:空白对照组(生理盐水);实验对照组(红牛);四组实验组。
给药方式及疗程
空白对照组灌胃同体积生理盐水,其他各组灌胃剂量如下:
实验对照组:同体积红牛;
四组实验组:0.2g/kg,纯净水溶解;
每天上午固定时间(9:00)对小鼠实施灌胃,灌胃体积为0.1ml·10g-1,给药持续28天。最后一次灌胃后1h进行行为学检测。
实验方法
1负重游泳实验
给药期间施行每3天一次,每次5min的无负重游泳适应性训练。各组小鼠在第28天灌胃1h后,以小鼠体质量7%的铅丝绑于小鼠的尾根部造成小鼠的负重状态,并立即放入50cm×40cm×40cm水箱游泳,控制水深不小于30cm,水温为25±1℃,用时间秒表记录自游泳开始至小鼠沉没后10s仍不能浮出水面的时间作为小鼠力竭游泳时间。记录小鼠首次下沉时间以及力竭时间。
2常压耐缺氧实验
于末次负重游泳实验后休息1天,第29天灌胃给药后1h,将每组中选择5只小鼠分别放入盛有5g钠石灰的250ml磨口瓶内,每瓶1只,用预先涂有凡士林的瓶塞密封瓶口,使之不漏气,立即计时,以呼吸停止为指标,记录小鼠因缺氧而死亡的时间。并根据以下标准进行缺氧耐受时间计算:T=(T1-T0)/(V0-W0/0.94)×100(式中,T1为小鼠死亡时间,T0为密闭开始的时间,V0为有效瓶容积,W0为小鼠体重,0.94为排水法测定的小鼠密度)。
3生理指标检测
负重游泳实验后待小鼠休息60分钟后,选择5只小鼠处死取血和肝脏,记录小鼠肝脏重量、体质量等在冰上静置1h后2500rpm,10min分离血清,按照试剂盒的说明检测小鼠血清乳酸(LD)、尿素氮(BUN)、肝糖原(LG)的含量。
4统计方法
实验数据以表示,采用GraphPadPrism8.02软件(GraphPadSoftware,Inc.,SanDiego,California,USA)进行统计分析。所有组别数据参数检验前进行了正态性检验(Kolmogorov-Smirnov检验)和方差齐性检验(Levene检验)。所有检验参数应用非成对T检验(单尾)进行组间两两比较,检验水准设定为p<0.05。
实验结果
1.负重游泳实验
编号 | 首次下沉时间(s) | 力竭游泳时间(S) |
实验组1(实施例1) | 33.92±5.84*** | 522.78±123.60*** |
实验组2(实施例2) | 34.74±6.48*** | 515.62±141.31*** |
实验组3(实施例3) | 36.86±7.31*** | 547.09±152.68*** |
实验组4(实施例4) | 37.68±4.98*** | 559.19±133.45*** |
实验对照组 | 20.13+3.12* | 332±87.42* |
空白对照组 | 16.31±2.54 | 97.55±18.48 |
表1中,*/**/***表示具有显著性差异。
2常压耐缺氧实验
编号 | 缺氧耐受时间(s) |
实验组1(实施例1) | 634.15±18.96*** |
实验组2(实施例2) | 644.12±22.61*** |
实验组3(实施例3) | 648.62±31.05*** |
实验组4(实施例4) | 639.80±28.61*** |
实验对照组 | 546.65±28.168* |
空白对照组 | 505.82±19.14 |
表2中,*/**/***表示具有显著性差异。
3.生理指标检测
编号 | LD(mmol/L) | BUN(mmol/L) | LG(mmol/L) |
实验组1(实施例1) | 3.68*** | 5.23*** | 18.01*** |
实验组2(实施例2) | 3.64*** | 5.44*** | 17.56*** |
实验组3(实施例3) | 3.71*** | 5.86*** | 17.81*** |
实验组4(实施例4) | 3.62*** | 5.50*** | 18.32*** |
实验对照组 | 6.21* | 8.68 | 12.21* |
空白对照组 | 7.32 | 9.24 | 10.12 |
表3中,*/**/***表示具有显著性差异。
虽然以上描述了本发明的具体实施方式,但是本领域的技术人员应当理解,这仅是举例说明,本发明的保护范围是由所附权利要求书限定的。本领域的技术人员在不背离本发明的原理和实质的前提下,可以对这些实施方式做出多种变更或修改,但这些变更和修改均落入本发明的保护范围。
Claims (7)
1.一种含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,以质量份计算,含有以下组分:
乳清蛋白25-50
胶原蛋白肽10-20
结晶果糖10-20
β-烟酰胺单核苷酸5-15
β-羟基-β-甲基丁酸钙1-10
1,6-二磷酸果糖1-10
瓜拉那提取物1-5
米糠脂肪烷醇微胶囊0.5-3
肌酸0.5-3
维生素B1 0.5-3
维生素B2 0.5-3
牛磺酸0.1-1。
2.根据权利要求1所述的含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,所述米糠脂肪烷醇微胶囊由以下步骤制备:
(1)称取二十八烷醇提取物,加热熔化后,加入Tween80,搅拌均匀,作为油相;
(2)将壁材溶解于水中,作为水相;
(3)在加热装置中,边搅拌边将油相逐渐加入到水相中,搅拌乳化喷雾干燥。
3.根据权利要求2所述的含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,所述壁材包括以质量份计算,含有以下组分:
阿拉伯胶 1
麦芽糊精 1
β-环糊精 2。
4.根据权利要求2所述的含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,所述步骤(1)中,二十八烷醇提取物与Tween80的比例1g:8ml。
5.根据权利要求2所述的含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,所述步骤(2)中,二十八烷醇提取物与壁材的质量比为1:9,壁材与水的比例为9g:80ml。
6.根据权利要求2所述的含米糠脂肪烷醇的消除疲劳的组合物,其特征在于,所述步骤(3)中,搅拌乳化的时间为≥4h,加热温度≥80℃,搅拌速率≥6000rpm。
7.权利要求1-6任一所述的含米糠脂肪烷醇的消除疲劳的组合物的制备方法,其特征在于,包括以下步骤:
(1)预混:取配方量的牛磺酸,维生素B2、维生素B1、肌酸进行混合,得物料A;
物料A、米糠脂肪烷醇进行混合,得物料B;
物料B和瓜拉那提取物进行混合,得物料B;
物料C和1,6-二磷酸果糖进行混合,得预混料;
(2)总混:取配方量的乳清蛋白、胶原蛋白肽、结晶果糖、β-烟酰胺单核苷酸、β-羟基-β-甲基丁酸钙,和预混料置于混合机中,混合均匀,出料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310177885.1A CN116058506A (zh) | 2023-02-28 | 2023-02-28 | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310177885.1A CN116058506A (zh) | 2023-02-28 | 2023-02-28 | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116058506A true CN116058506A (zh) | 2023-05-05 |
Family
ID=86182010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310177885.1A Pending CN116058506A (zh) | 2023-02-28 | 2023-02-28 | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116058506A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107772446A (zh) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | 一种用于速度力量类的高蛋白营养物组合及其制备方法 |
CN109674035A (zh) * | 2019-01-21 | 2019-04-26 | 广州正广生物科技有限公司 | 一种缓解体力疲劳的组合物及其制备方法 |
CN112137095A (zh) * | 2020-09-27 | 2020-12-29 | 南京圣诺生物科技实业有限公司 | 一种运动营养组合物及其制备方法 |
CN112890066A (zh) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | 一种调血脂、抗疲劳、增强免疫力的固体饮料及其应用 |
-
2023
- 2023-02-28 CN CN202310177885.1A patent/CN116058506A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107772446A (zh) * | 2016-08-26 | 2018-03-09 | 华仁药业股份有限公司 | 一种用于速度力量类的高蛋白营养物组合及其制备方法 |
CN109674035A (zh) * | 2019-01-21 | 2019-04-26 | 广州正广生物科技有限公司 | 一种缓解体力疲劳的组合物及其制备方法 |
CN112137095A (zh) * | 2020-09-27 | 2020-12-29 | 南京圣诺生物科技实业有限公司 | 一种运动营养组合物及其制备方法 |
CN112890066A (zh) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | 一种调血脂、抗疲劳、增强免疫力的固体饮料及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mironenko et al. | Magnesium (Mg, Magnesium)–description, effect on the body, the best sources of magnesium | |
CN103211265A (zh) | 一种具有抗疲劳保健功效的饮料及其制作方法 | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
CN102160664A (zh) | 儿童营养饮料 | |
CN106418545A (zh) | 一种营养均衡的功能性食品 | |
CN101642176A (zh) | 一种缓解神经衰弱的酸枣蜂蜜茶的制作方法 | |
CN101248880A (zh) | 一种抗疲劳运动饮料及其制备方法 | |
CN104126803A (zh) | 一种补充心脑营养与舒心益脑的保健品 | |
CN109288005B (zh) | 一种具有辅助改善记忆力功能的组合物、其应用及制备方法 | |
CN103238889B (zh) | 一种抗疲劳苹果醋保健饮料及其制备方法 | |
CN110801018A (zh) | 辅酶q10维生素c运动含片 | |
CN108902719A (zh) | 一种保健面条及其制备方法 | |
WO2024055835A1 (zh) | 一种解酒护肝饮品及其制备方法 | |
CN112772809A (zh) | 一种运动训练专用饮料及其制备方法 | |
CN101675800B (zh) | 一种妇女产后滋补膏及制备方法 | |
CN106418067A (zh) | 一种补充体力、缓解疲劳的保健饮料 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
CN116058506A (zh) | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 | |
CN102204676A (zh) | 一种抗睡眠剥夺应激损伤的食品 | |
CN115252768A (zh) | 一种改善男性生殖能力的组合物、制备方法和应用 | |
CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
CN114010750A (zh) | 一种补肾生血抗衰的参草方 | |
CN103027926A (zh) | 一种用于营养补充剂的药物组合物及其口服液制备方法 | |
CN106036387A (zh) | 超级藜麦儿童生长营养包 | |
CN105647774A (zh) | 一种番荔枝果醋及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230505 |